Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Inhaled Fenotereol,Ipratroium Plus Beclomethasone Versus Salmeterol,Tiotropium Plus Fluticasone in Frequent Excerbator COPD Patients

ID
Name
SABA,SAMA versus LABA,LAMAcopd
Description
Chronic obstructive pulmonary disease is heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive ,airflow obstruction. There are network meta analysis to compare the efficacy and safety of short acting bronchodilators Vs long acting agents in treatment of COPD
Trial arms
Trial start
2023-02-20
Estimated PCD
2024-02-20
Trial end
2024-03-20
Status
Not yet recruiting
Phase
Early phase I
Treatment
SABA SAMA ICS Vs LABA LAMA ICs
Short acting agents,long acting agents ,ics
Arms:
LABA,LAMA ICS, SABA,SAMA ICS
Size
80
Primary endpoint
to assess improvement of symptoms mainly dyspnea
1 year
Eligibility criteria
Inclusion Criteria: * All frequent exacerabator copd patients Exclusion Criteria: * patients less than 18
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}
Updated at
2023-03-01

1 organization

1 product

1 indication

Organization
Assiut University
Product
SABA SAMA ICS Vs LABA LAMA ICs
Indication
Chronic obstructive pulmonary disease